Steven Smith
Endocrinology, Diabetes & Metabolism · Orlando, FLNPI 1497988927
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $325,885 of the $389,507 with a category attached, or 83.7%. Zealand Pharma A/s accounts for 77.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $321,966 and has fallen 98.3% since, to $5,625 in 2025. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $2928.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zealand Pharma A/s$301K
- Novo Nordisk$37K
- Eli Lilly$23K
- Boehringer Ingelheim$18K
- Eisai Inc.$5K
- Genentech, Inc.$4K
- plus $1K from 6 others
Across 26 payments — averaging $289,854 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$3.3M
- Eli Lilly$2.4M
- Pfizer$1.1M
- Sanofi US Services Inc.$706K
- Visby Medical, Inc.$45K
- Amgen$652
What the payments were for
- Consulting fees$325,88584%
- Speaking & faculty fees$8,3532%
- Travel & lodging$50,95813%
- Food & beverage$4,3111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zealand Pharma A/s | 50 | $300,663 |
| Novo Nordisk | 19 | $37,026 |
| Eli Lilly | 30 | $23,267 |
| Boehringer Ingelheim | 20 | $18,065 |
| Eisai Inc. | 2 | $4,995 |
| Genentech, Inc. | 5 | $4,149 |
| Regeneron | 1 | $548 |
| Boehringer Ingelheim International GmbH | 2 | $266 |
| E.r. Squibb & Sons, L.L.C. | 1 | $199 |
| Medtronic | 1 | $175 |
| Stryker | 1 | $106 |
| Corcept Therapeutics | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$7,650
- MOUNJARO$5,625
- Non-Covered Product$4,133
- Signia$175
- VSP SYSTEM, VSP CRANIAL$106
- DELTA$106
How this compares
$389,507 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Other endocrinology, diabetes & metabolism in Orlando
- Damon TantonOrlando$1.2M
- Richard PratleyOrlando$735K
- Hanford YauOrlando$489K
- Tina ThethiOrlando$244K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.